Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. OvermanThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: [email protected]Ray McDermottSt Vincent's University Hospital and Cancer Trials Ireland, Dublin, IrelandJoseph L. LeachAllina Health System, Minneapolis, MN, USASara LonardiIstituto Oncologico Veneto IOV-IRCSS, Padova, ItalyHeinz‐Josef LenzUSC Norris Comprehensive Cancer Center, Los Angeles, CA, USAMichael A. MorseDuke University Medical Center, Durham, NC, USAJayesh DesaiRoyal Melbourne Hospital/Peter MacCallum Cancer Centre, Victoria, VIC, AustraliaAndrew HillTasman Oncology Research Ltd, Southport, Queensland, QLD, AustraliaMichael D. AxelsonBristol-Myers Squibb, Princeton, NJ, USARebecca A. MossBristol-Myers Squibb, Princeton, NJ, USAMonica V. GoldbergBristol-Myers Squibb, Princeton, NJ, USAZ. Alexander CaoBristol-Myers Squibb, Princeton, NJ, USAJean-Marie LedeineBristol-Myers Squibb, Braine-L'Alleud, BelgiumGregory A. MaglinteBristol-Myers Squibb, Princeton, NJ, USAScott KopetzThe University of Texas MD Anderson Cancer Center, Houston, TX, USAThierry AndréHôpital Saint Antoine, Assistance Publique Hôpitaux de Paris and Sorbonne Universités, UMPC Paris 06, Paris, France
2017en
ABI
Аннотация
Аннотация мавжуд эмас.
Идентификаторлар
Иқтибослар ва манбалар
2 та иқтибос0 та фойдаланилган манба